Next Article in Journal
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
Previous Article in Journal
pH Dependent Antimicrobial Peptides and Proteins, Their Mechanisms of Action and Potential as Therapeutic Agents
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2016, 9(4), 68; doi:10.3390/ph9040068

The Development of a Parenteral Pharmaceutical Formulation of a New Class of Compounds of Nitrosourea

1
Ministry of Health of Russian Federation, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia
2
Ministry of Health of Russian Federation, Federal State Budgetary Scientific Institution, N.N. Blokhin Russian Cancer Research Center, Moscow 115478, Russia
*
Author to whom correspondence should be addressed.
Academic Editors: Thomas Rades and Jean Jacques Vanden Eynde
Received: 13 May 2016 / Revised: 24 October 2016 / Accepted: 25 October 2016 / Published: 1 November 2016
View Full-Text   |   Download PDF [987 KB, uploaded 1 November 2016]   |  

Abstract

Despite the rapid development of medical technologies, chemotherapy treatment still occupies an important place in clinical oncology. In this regard, the current research in this area focuses on the synthesis of new highly effective antitumor substances that have minimal side effects and the development of stable pharmaceutical formulations (PF) on their basis. In order to solve this problem, the I. Ya. Postovsky Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences actively sought for original substances, namely, nitrosourea (NU) derivatives, one of the most promising classes of anticancer drugs. As a result of this research, a novel NU derivative was synthesized, namely ormustine, which showed high antitumor activity in preliminary preclinical trials. It is now crucial to develop an ormustine pharmaceutical formulation. Conducted technological studies showed that the most suitable solvent for the drug substance is 0.1 M hydrochloric acid, which ensures its rapid dissolution by ultrasonic treatment. A significant reduction in the concentration of the active ingredient during the storage of the solution required the development of a technique of its lyophilization and the selection of a shaper such as a Kollidon 17 PF. Upon completion of the development of a pharmaceutical formulation of ormustine, its stability after lyophilization was demonstrated, and a sufficient amount of the drug has been acquired for preclinical research. View Full-Text
Keywords: ormustine; solvents; sterilizing filtration; lyophilization ormustine; solvents; sterilizing filtration; lyophilization
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nikolaeva, L.; Oborotova, N.; Bunyatyan, N.; Zhang, X.; Sanarova, E.; Lantsova, A.; Orlova, O.; Polozkova, A. The Development of a Parenteral Pharmaceutical Formulation of a New Class of Compounds of Nitrosourea. Pharmaceuticals 2016, 9, 68.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top